GIMV N.V. (0EKR IL) stock market data APIs

Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer 2020; Connected Consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer 2020, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. It mainly focuses on European market and midcap companies in Flanders and Brussels, and also invests in Kazakhstan, Benelux, Germany, France, Italy, Luxembourg, Netherlands, United Kingdom, Russia, Czech Republic, and Slovakia. Within consumer 2020, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. It invests in small and medium sized businesses primarily with headquarters in the Benelux, France, and Germany with an enterprise value of up to "125 million ($144.76 million). It seeks to invest between "3 million ($3.47 million) to "30 million ($34.74 million). Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as me